Search Results for medicines

Blackstone

Execution of Sub-license Agreement from Ping An-Shionogi Hong Kong to Juniper Therapeutics and SAR approval in Singapore regarding ensitrelvir fumaric acid, a treatment drug for the novel coronavirus infection (COVID-19)

Shionogi & Co., Ltd.  (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced Ping An-Shionogi (Hong Kong) Limited (Head Office: Hong Kong, China; Chairman and Chief Executive Officer: Tatsumori Yoshida; hereafter “Ping An-Shionogi Hong Kong”) and…

Read MoreExecution of Sub-license Agreement from Ping An-Shionogi Hong Kong to Juniper Therapeutics and SAR approval in Singapore regarding ensitrelvir fumaric acid, a treatment drug for the novel coronavirus infection (COVID-19)

BioMarin Announces Governance Enhancements and Value Creation Initiatives

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation. The Board has approved the appointment of three new independent directors: Barbara…

Read MoreBioMarin Announces Governance Enhancements and Value Creation Initiatives

EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel Consortium (Consortium). The Consortium announced that the Committee for Medicinal Products…

Read MoreEMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

ICON wins industry accolades from TIME Magazine, Forbes and Financial Times in second half of 2023

 ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation (CRO), finishes the second half of 2023 with positive recognition as a top-rated employer and leader in clinical trial innovation.  In recognition of its Environmental, Social and Governance (ESG)…

Read MoreICON wins industry accolades from TIME Magazine, Forbes and Financial Times in second half of 2023

argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced topline results from the ADDRESS study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults…

Read Moreargenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

Decision to Invest over 20 Billion Yen in Bio Drug Substance Manufacturing Building “UK3” to Expand its Production Capacity and towards Realizing Halogenated Hydrocarbon-Free

 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced its decision today to invest in its Bio drug substance (DS) manufacturing facility “UK3” in the Ukima Plant (Kita-ku, Tokyo) of Chugai Pharma Manufacturing Co., Ltd. (Head office: Tokyo, President: Shinya Takuma), a member…

Read MoreDecision to Invest over 20 Billion Yen in Bio Drug Substance Manufacturing Building “UK3” to Expand its Production Capacity and towards Realizing Halogenated Hydrocarbon-Free

EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness found in East and Southern Africa

Sanofi, DNDi and the HAT-r-ACC consortium announce the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion of Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense).…

Read MoreEMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness found in East and Southern Africa